Tissue-specific and target RNA-specific ribozymes

Details Tissue-specific and target RNA-specific ribozymes Tissue-specific and target RNA-specific ribozymes

2002-02-26

2010-06-08

Epps-Smith, Janet L (Department: 1633)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C424S450000, C435S320100, C435S375000, C536S023100, C536S023200, C536S024100, C536S024500, C514S04400A

Reexamination Certificate

active

07732197

ABSTRACT:
The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present invention relates to the use of virions and viral vectors to package and deliver DNA encoding the multi-ribozymes to a host. The present invention relates to the use of liposomes and lipid-DNA complexes to deliver DNA encoding ribozymes to a host. Most specifically, the invention relates to the use of target specific virions to package and deliver DNA comprising a target specific promoter and encoding a ribozyme(s) directed to the target organism nucleic acids. The present invention further relates to a novel vectors encoding a multi-ribozyme structure with enhanced 5′ and/or 3′ autocatalytically cleaving ribozymes. The invention further relates to nucleotides encoding a multi-ribozyme comprising one or more ribozyme cassettes which contain one or more trans-acting ribozymes and one or more autocatalytically cleaving ribozyme sequences.

REFERENCES:
patent: 5166057 (1992-11-01), Palese et al.
patent: 5294533 (1994-03-01), Lupski et al.
patent: 5436330 (1995-07-01), Taira et al.
patent: 5500357 (1996-03-01), Taira et al.
patent: 5578473 (1996-11-01), Palese et al.
patent: 5599706 (1997-02-01), Stinchcomb et al.
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5824519 (1998-10-01), Norris et al.
patent: 5912149 (1999-06-01), Ruiz et al.
patent: 6271359 (2001-08-01), Norris et al.
patent: 2003/0125280 (2003-07-01), Norris et al.
patent: 0 640 688 (1995-03-01), None
patent: WO 90/00624 (1990-01-01), None
patent: WO 92/10590 (1992-06-01), None
patent: WO 94/03594 (1994-02-01), None
patent: WO 95/07923 (1995-03-01), None
patent: WO 97/17433 (1997-05-01), None
patent: WO 97/17458 (1997-05-01), None
patent: WO 9717433 (1997-05-01), None
patent: WO 98/17815 (1998-04-01), None
patent: WO 98/17816 (1998-04-01), None
patent: WO 98/17817 (1998-04-01), None
patent: WO 98/24925 (1998-06-01), None
patent: WO9824925 (1998-06-01), None
patent: WO 99/67400 (1999-12-01), None
Ohta et al. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic acid Research, vol. 24. No. 5, pp. 938-942, 1996.
Stanley Crooke, Antisense Research and Applications, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, Berlin, Heidelberg, New York, p. 3, 1998.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, 1998.
U.S. Appl. No. 09/291,902, filed Apr. 14, 1999, Norris et al.
U.S. Appl. No. 09/319,395, filed Jun. 3, 1999, Norris et al.
Bassford et al., “The Primary Pathway of Protein Export inE. coli,” Cell, 1991, 65:789-796, 30:367-368.
Bertrand et al., “Can hammerhead ribozymes be efficient tools to inactivate gene function?”Nucleic Acids Resonant., 1994, 22(3):293-300
Bouche et al., “dnaG gene product, a rifampicin resistant RNA polymerase, initiates the conversion of a single stranded coliphage DNA to its duplex replicative form,”J. Biol. Chem., 1975, 250:5995-6001.
Castanotto et al., “Antisense Catalytic RNAs as Therapeutic Agents,”Adv. Pharmacol., 1994, 25:289-317.
Christoffersen et al., “Ribozymes as human therapeutic agents,”J. Med. Chem., 1995, 38(12):2023-2037.
Clawson et al., “Focal altered compartmentation of repetitive B2 (Alu-like) sequences in rat liver following hepatocarcinogen exposure,”Cell Growth Differ., 1996, 7(5):635-646.
Colberre-Garapin et al., “A new dominant hybrid selective marker for higher eukaryotic cells,”J. Mol. Biol. 1981, 150(1):1-1.
Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure,”Proc. Natl. Acad. Sci. USA, 1987, 84:7413.
Gewirtz et al., “Facilitating oligonucleotide delivery: helping antisense deliver on its promise ”Proc. Natl. Acad. Sci. USA, 1996, 93:3161-3163.
Greenberg et al., “The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice,”Mol Endo., 1994, 8(2):230-239.
Haseloff et al., “Simple RNA enzymes with new and highly specific endoribonuclease activities,”Nature, 1988, 334:585-591.
Inokuchi et al., “A hammerhead ribozyme inhibits the proliferation of an RNA coliphage SP inEscherichia coli,” J. Biol. Chem., 1994, 269(15):11361-11366.
Koizumi et al., “Design of RNA enzymes distinguishing a single base mutation in RNA,”Nucl. Acids Res., 1989, 17(17):7059-7071.
Lehnherr et al., “Plasmid addiction genes of bacteriophage P1: doc, which causes cell death on curing of prophage, and phd, which prevents host death when prophage is retained,”J Mol Biol., 1993, 233:414-428.
Major et al., “The combination of symbolic and numerical computation for three-dimensional modeling of RNA,”Science, 1991, 253:1255-1260.
Marians, “Replication Fork Propagation,”Escherichia coli and Salmonella: Cellular and Molecular Biology, 2ndEdition, vol. 1, Neidhard (ed.), American Society for Microbiology, Washington, D.C., 1996, pp. 749-763.
Merril et al., “Long-circulating bacteriophage as antibacterial agents,”Proc. Natl. Acad. Sci. USA, 1996, 93(8):3188-3192.
Meyer et al., “Search for a putative scrapie genome in purified prion fractions reveals a paucity of nucleic acids,”J. Gen. Virol., 1991, 72:1031-1038.
Miller et al., “Progress in transcriptionally targeted and regulatable vectors for genetic therapy,”Hum. Gene Ther., 1997, 8:803-815.
Nicolau et al., “Liposomes as carriers for in vivo gene transfer and expression,”Methods Enzymol., 1987, 149:157.
Ohkawa et al., “Activities of HIV-RNA targetter ribozymes transcribed from a ‘shot-gun’ type ribozyme-trimming plasmid,”Nucl. Acids Symp. Ser., 1992.
Ohme-Takagi, “In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes,”Nucl. Acids Symp. Ser., 1990, 22:49-50.
Pace and Smith, “Ribonuclease P: function and variation,”J. Biol. Chem. 1990, 256(7):3587-3590.
Palese et al., “Negative-strand RNA viruses: genetic engineering and applications,”Proc. Natl. Acad. Sci. USA, 1996, 93:11354-11358.
Poulsen et al., “The gef gene fromEscherichia coliis regulated at the level of translation,”Mol. Microbiol., 1991, 5:1639-1648.
Schmidt et al., “Regulation ofEscherichia colisecA mRNA translation by a secretion-responsive element,”J. Bacteriol. 1991, 173 20 :6605-6611.
Schmidt and Delihas, “micF RNA is a substrate for Rnase E,”FEMS Microbiol. Lett., 1995, 133(3):209-213.
Slopek et al., “Results of bacteriophage treatment of suppurative bacterial infections in the years,”Arch. Immunol. Ther. Exp. (Warz), 1987, 35:569-583.
Soothill, “Treatment of experimental infections of mice with bacteriophages,”J. Med. Microbiol., 1992, 37(4):258-261.
Sternberg, “Recognition and cleavage of the bacteriophage P1 packaging site (pac) II. Functional limits of pac and location of pac cleavage termini,”J. Mol. Biol., 1987, 194(3):469-479.
Stull et al., “Antigene, ribozyme and aptamer nucleic acids drugs: progress and prospects,”Pharm. Res., 1995, 12(4):465-483.
Sullivan et al., “Development of ribozymes for gene therapy,”J. Invest. Dermatol., 1994, 103:85S-95S.
Taira et al., “Construction of a novel RNA-transcript-trimming plasmid which can be used both in vitro in place of run-off and (G)-free transcriptions and in vivo as multi-sequences transcription vectors,”Nucl. Acids Res., 1991, 19(9):5125-5130.
Taira et al., “Construction of several kinds of ribozymes their reactivities and utilities,”Gene Regulation, Biolog

Affiliated with

Also associated with

Rating

Tissue-specific and target RNA-specific ribozymes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tissue-specific and target RNA-specific ribozymes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue-specific and target RNA-specific ribozymes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4203302